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Allogeneic bone marrow transplant (BMT) was first performed 
successfully at St. Francis Medical Center in 1978. Since that 
time, 91 BMTs have been performed for aplastic anemia, leuke-
mia, lymphoma, and Stage II, Ill and IV breast cancers. This 
article will explain the methods, complications and results of 
BMT in Hawaii. 
Methods 
Bone marrow transplant experience in Hawaii has been that 
of purged ornon-purged autologous and allogeneic. Autologous 
is defined as marrow taken from the patient. It is purged with 
chemotherapeutic agents or monoclonal antibodies if marrow is 
involved with tumor, or non-purged if marrow is not involved 
with tumor. The marrow is stored after being frozen with liquid 
nitrogen. The patient is treated with total body irradiation, 
fractionated 225 rads for 5 doses and/or with chemotherapeutic 
agents such as cyclophamide (CTX), etoposide (VP 16), busulfan 
(BU), and carmustine (BCNU) in escalated doses ( 4 to 10 times 
normal doses). After chemotherapy and/or radiation, the mar-
row is thawed andre-infused into the patient through a central 
venous catheter. 
Allogeneic transplant is performed between a donor and 
recipient. The healthy donor usually is an HLA-identical sibling, 
although HLA-identical unrelated donors recently have been 
used. The 6th chromosome harboring the HLA locus must be 
identical or with no more than 1 mismatch in the 6 antigens. The 
ABO blood type locus in the 9th chromosome can be crossed and 
a mismatch also may result in similar good results. In Hawaii, a 
donor is found by HLA typing of family members or through 
local and national registries. The donor must be free ofhepatitis, 
AIDS, and in good physical condition. The recipient must be 
young and otherwise healthy with no infectious disease, diabe-
tes, cardiac disease or severe respiratory problems. Once a 
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donor/recipient pair is identified, the recipient undergoes total 
body irradiation of fractionated 225 rads for 5 doses, and/or 
receives chemotherapy with CTX,VP 16, BU, or BCNU. Fol-
lowing this, the patient is allowed to rest for 48 hours. The donor 
marrow is then harvested and infused into the recipient within 24 
hours. The amount of marrow given is 3 x 108 of nucleated cells 
per kilogram of recipient weight. 
After infusion of marrow, the recipient is maintained in a 
special room with Hepafilter air conditioning and 10 mm of 
positive pressure. The patient is maintained on a specific diet 
consisting of no fresh fruits or vegetables, and all meals are 
thoroughly cooked to avoid this source of infection. Specific 
oral antibiotics and antifungal medications are given prophylac-
tically. Visitors must comply with strict rules for washing their 
hands and must wear masks and gloves to avoid contaminating 
these immunosuppressed patients. Hospitalization for 30 to 500 
days generally is needed to reconstitute marrow and obtain a 
WBC > 4,000 cells/mm3• The patient is given granulocyte-
colony stimulating factor (G-CSF) or granulocyte and macroph-
age-colony stimulating factor (GM-CSF) in order to stimulate 
WBC production. RBCs are slower to reconstitute and platelets 
may require 3 to 6 months before the count becomes normal. 
Although the WBC count may become normal, the function 
of these cells can be depressed for as long as a year. These 
patients will require monthly intravenous immunoglobulin and 
cyclosporine for 6 months. If all goes well, at the end of the 6 
months, these patients are on no medication and can behave 
almost normally. At the end of 1 year, the majority who survive 
in a disease-free state are as healthy as any in their age group. 
Results 
Sixty-seven allogeneic bone marrow transplants have been 
performed at St. Francis Medical Center (SFMC) for various 
stages ofleukemia, aplastic anemia, and lymphoma since 1978 
and the majority of these were for advanced disease. When 
broken down by age groups, stage of disease, and type of 
disease, the numbers of patients for each category would be a 
relatively small3 to 5 for each category. Comparisons for such 
small numbers would not be meaningful. At present, 23 are 
alive, in complete remission and disease-free: One patient is 
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alive with recurrent disease; of the 23 who are alive, 19 are back 
to full employment and activity, 2 are at home and 2 remain 
hospitalized. 
Sixteen autologous harvests have been performed at SFMC, 
followed by 11 transfusions: Five of these patients are in 
remission and disease-free and 6 have died. Four autologous 
purged BMTs have been performed; 2 have survived in com-
plete remission (disease-free). The first was done in conjunction 
with Kapioloni Medical Center for Women and Children. 
Discussion 
Autologous BMT, purged or non-purged, has been per-
formed in Hawaii for: Leukemia in remission, lymphoma with 
minimal or no bone involvement, and breast cancer as an 
adjutant therapy in those patients with 10 or more positive nodes 
or metastatic disease. Allogeneic BMT is performed for aplastic 
anemia, acute leukemias, chronic leukemias, and lymphoma. 
Currently, there appears to be no benefit of allogeneic BMT in 
solid tumors. 
The results from our center are comparable to many U.S. 
centers. The success rate for bone marrow transplant is quite 
variable and depends on: 1) age, 2) disease type: acute myelog-
enous leukemia(AML), chronic myelogenous leukemia (CML), 
acute lymphoblastic leukemia (ALL), Lymphoma- B-cell, T-
cell, Hodgkin's or non-Hodgkin's, 3) stage of disease (first 
remission, relapse, second remission, second relapse, acceler-
ated disease or blastic crisis), and 4) overall physical condition 
of the patient. 
1) Age. Allogeneic BMTs generally are limited to the younger 
patient. Those patients under 20 years of age have the best 
results. Intermediate results occur in 20 to 30-year olds, and 
BMT is contraindicated in those over 45 years of age because of 
the high morbidity and mortality. 
2) Type of disease. Aplastic anemia has excellent results bor-
dering on 75% complete remission after BMT. Good results are 
obtained from AML and CML, with long-term disease-free 
states. BMT for ALL results in high recurrence rates and lower 
long-term disease-free states. The outcome for lymphoma de-
pends largely on the extent of disease and the presence of 
chromosomal abnormalities. Extensive disease with chromo-
somal abnormalities invariably yields poor long-term disease-
free states. 
3) State of disease. Optimal results for allogeneic BMT occur 
when done early after diagnosis when the disease is in first 
remission. Transplantation done in blastic crisis yields 10% or 
less long-term disease-free remission. 
4) Patient condition. The overall physical condition of the 
patient is important to the success of BMT. Patients with other 
diseases such as diabetes, cardiac problems, cerebrovascular 
disease, hepatitis, and AIDS are disqualified from allogeneic 
BMT because of the associated high morbidity and mortality. 
Thus, the ideal candidate for BMT would be an otherwise 
healthy 20 year-old with AML in first remission. This would 
yield the lowest mortality and 50% to 60% long-term disease-
free state. Likewise, a 30-year old with CML who is transplanted 
-
before the third year of diagnosis and not in accelerated phase or 
blastic crisis also would be a good candidate. 
Complications from BMT are numerous; the more frequent 
ones are listed here: 
1. Graft versus host disease (GVHD). This occurs when the 
graft views the body as foreign and attempts to reject either the 
body as a whole or specific organs. This process is a function of 
activated T -lymphocytes which attack the liver, gastrointestinal 
tract, lungs, and skin. GVHD can be fatal even in HLA-identical 
donors and mortality can be as high as 10% and varies with age. 
Younger patients experience GVHD less than older patients. 
GVHD also brings about GVL (Graft versus Leukemia), a 
beneficial response. Radiation and chemotherapy are a Log kill 
ofleukemic cells. The probability of all tumor being eliminated 
by chemotherapy or radiation is small. With GVL, in all likeli-
hood, the graft will be able to eradicate any remaining leukemic 
cells. 
2. Pharyngitis. Severe pharyngitis is caused by high-dose che-
motherapy and total body irradiation. This pharyngitis lasts for 
2 to 3 weeks and keeps the patient from being able to swallow, 
drink, or eat; total parenteral nutrition is needed during this 
period. 
3. Infections. Bacterial infections are common early complica-
tions; however, long-term antibiotic therapy for these may result 
in later fungal infections. Viral infection such as cytomegalovi-
rus, adenovirus, and herpes zoster tend to occur years later. 
Appropriate therapy is needed to prevent and treat each of the 
specific organisms. 
4. Rejection. Rejection of the graft can occur causing prolonged 
aplasia and accompanying complications. A second graft could 
be required to achieve good engraftment. 
5. Sterility. High-dose chemotherapy and/or fractionated Total 
Body Irradiation will cause sterility, although male and female 
hormones will be produced in the usual amounts. 
6. Drug effects. Use of immunosuppressive medications can 
result in many untoward effects. Use of steroids can result in 
Cushingoid appearance, peptic ulcer disease, and cataracts. 
Cyclosporine in high doses can result in seizures, hypertension, 
headaches, and nephrotoxicity. 
7. Other complications. There are many other complications 
that occur less frequently: Hypothyroidism, veno-occlusive 
disease, de novo tumors such as lymphoma and leukemias, and 
interstitial pneumonia. 
The program in Hawaii has been approved for Southwest 
Oncology Group (SWOG), Eastern Cooperative Oncology Group 
(ECOG), and Pediatric Oncology Group (POG) protocols. Site 
visitshavebeenperformedbySWOGandECOG,andtheyhave 
provided full approval for allogeneic and autologous BMT 
under research protocol. 
Under the leadership of Y.K. Paik MD, this program has 
developed a National Marrow Donor Pool (NMDP) of local 
donors. Donor marrow has been collected in Hawaii and sent to 
Canada, Washington, Tennessee, and California. 
~ Continued on page 84 
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Table 2 Donors. Cause of Brain Death 
Head Trauma 
Intracranial Bleeding 
Brain Tumor 
MVA=Motor Vehicle accident 
GSW=Gunshot Wound 
MVA 
GSW 
Fall 
8 
5 
1 
5 
the whole plasma volume as plasmapheresis does. This treat-
ment modality has been used in the recent past, and there are no 
reports with large experiences available. We have shown that it 
is an effective way of treating this devastating complication. In 
one patient, we stopped the azathioprine and substituted it with 
cyclophosphamide which has more specific effect on the anti-
body production limb of the immune response. This change 
seems to have controlled the humoral rejection in a better way. 
A serious problem in long-term survivors is the appearance of 
graft coronary atherosclerosis. Stanford reports a 25% incidence 
at 5 years,2 and it seems to correlate with CMV infections. 
Currently, there is no effective way of preventing this complica-
tion. The only effective treatment once it is advanced is 
retransplantation. Fortunately, we have not seen this problem 
frequently in our patients. Only one patient has had significant 
coronary artery obstruction which had no clinical manifesta-
tions. 
Infectious complications have not been a major problem in 
our patient population. It is well known that opportunistic 
infections, mostly fungal and viral, are prevalent in transplanted 
patients. With one exception, all infectious episodes have been 
adequately treated. 
Cardiac transplantation is an expensive procedure. Nonethe-
less, studies have shown this operation to be cost-effective. It is 
clear that most patients with end-stage cardiac disease are 
disabled, many of them being unable to work with resultant loss 
of income, and others have repeated or prolonged hospitaliza-
tions with accumulating health care costs. A transplant opera-
tion often reverses this downhill trend and can return the patient 
to a functional status. The results are not optimal yet and further 
improvements are expected as more experience accumulates, 
but great advances have been made in the past 3 decades. This 
endeavor requires a monumental effort from different institu-
tions and many individuals. The main reward that professionals 
involved in transplantation receive is seeing a patient recover 
from a devastating disease. 
Addendum 
Since the completion of this study, one more patient, our 
longest survivor (who lived more than 6 years) died in January 
1994. The cause of death has not been determined, however his 
death does not alter the 1-year, 3-year or 5-year survival statistics. 
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The Hawaii BMT program also has been investigated by 
NMDP. Approval has been given for St. Francis Medical Center 
as one of 72 hospitals capable of performing unrelated alloge-
neic BMT transplants from the world's pool of potential donors. 
Summary 
Allogeneic and autologous bone marrow transplantation has 
been performed in Hawaii since 1978 for leukemia, lymphoma, 
aplastic anemia, and advanced breast cancer. The numbers for 
each group are relatively small and the disease stages are 
diverse. Our program has been recognized and approved by the 
various national organizations, and we hope to continue to 
provide this treatment alternative to appropriate candidates. 
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